new glp-1 drug retatrutide Weight Loss Results:Trial Data and FDA Status Retatrutide Triple Agonist (GLP-1/GIP/GCG) |
Description
For detailed comparison of outcomes with these medications, see our Mounjaro vs Ozempic comparison
doi: 10.1210/clinem/dgz140 169 KhooTKLinJ
From 2016 to 2020, the compound annual growth rate of long-acting GLP-1 agonists was as high as 50.1%, much higher than the 5.6% for short-acting GLP-1 agonists
GLP-1 agonists are weight loss medicines like tirzepatide and semaglutide
